Why Gilead Sciences Remains A Buy After A 40% Rally

Group 1 - Gilead Sciences' share price has increased by over 40% since the last article published in late August of the previous year [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [2] - The firm aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]